Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.63 |
| ▸ | CPB1 | P15086 | 1/20 | 0.63 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.63 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674796 | 0.97 | ECE1 (0.59) | ECE1CPB1CPB2ITGB3ITGA2B | |
| SCHEMBL10035700 | 0.90 | CTSK (0.55) | ECE1CPB1CPB2ITGB3ITGA2B | |
| SCHEMBL7279464 | 0.90 | CTSK (0.55) | ECE1CPB1CPB2ITGB3SIRT2 | |
| SCHEMBL10035721 | 0.90 | CTSK (0.55) | ECE1CPB1CPB2ITGB3ITGA2B | |
| SCHEMBL287474 | 0.89 | ITGB3 (0.66) | ECE1CPB1CPB2ITGB3ITGA2B | |
| SCHEMBL287475 | 0.89 | ITGB3 (0.66) | ECE1CPB1CPB2ITGB3ITGA2B | |
| SCHEMBL15968143 | 0.89 | ITGB3 (0.66) | ECE1CPB1CPB2ITGB3ITGA2B | |
| SCHEMBL6476819 | 0.89 | ITGB3 (0.66) | ECE1CPB1CPB2ITGB3ITGA2B | |
| SCHEMBL29387284 | 0.89 | CPB1 (0.55) | ECE1CPB1CPB2ACESIRT2 | |
| SCHEMBL3798058 | 0.89 | ECE1 (0.64) | ECE1CPB1CPB2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025055942-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025055943-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| EP-4511367-A1 | FAP INHIBITORS | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-02-26 | — | — | EP | disclosed |
| CN-119072472-A | FAP inhibitors | 上海先通生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-11946079-B2 | Method for producing a protein hydrolysate using an endopeptidase and a carboxypeptidase | NOVOZYMES A/S (DK) | 2024-04-02 | — | — | US | disclosed |
| WO-2024022332-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023202655-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2023-10-26 | — | — | WO | disclosed |
| US-20220127592-A1 | POLYPEPTIDE, USE AND METHOD FOR HYDROLYSING PROTEIN | NOVOZYMES A/S (DK) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | ECE1 1542/4885CPB1 136/4885CPB2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.